While developing new therapeutic approaches based on PP1/PP2A targeting is a promising direction in the treatment of ALI/ARDS, it is a highly challenging area of research due to broad substrate specificity along with the high structural similarity of the free catalytic subunits and high complexity of protein interactomes of PPP family PPases (i.e., PP1 and 2A) [39,40,41]. The gene discussed is PPA1; the disease is acute respiratory distress syndrome.